Allogeneic Stem Cell Transplantation of NiCord, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells, in Adolescent and Adult Patients With Hematological Malignancies

Trial Profile

Allogeneic Stem Cell Transplantation of NiCord, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells, in Adolescent and Adult Patients With Hematological Malignancies

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 01 Aug 2018

At a glance

  • Drugs Cord blood stem cell therapy (Primary)
  • Indications Haematological malignancies
  • Focus Therapeutic Use
  • Sponsors Gamida-Cell
  • Most Recent Events

    • 27 Jul 2018 Trial has been completed in Netherlands (End date:2018-06-29).
    • 30 Apr 2018 According to a Gamida-Cell media release, data will be presented at the International Society for Cellular Therapy (ISCT) Annual Meeting.
    • 19 Mar 2018 Results published in the Gamida-Cell Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top